HNRPK_RAT
ID HNRPK_RAT Reviewed; 463 AA.
AC P61980; Q07244; Q15671; Q60577; Q922Y7; Q96J62;
DT 07-JUN-2004, integrated into UniProtKB/Swiss-Prot.
DT 07-JUN-2004, sequence version 1.
DT 03-AUG-2022, entry version 166.
DE RecName: Full=Heterogeneous nuclear ribonucleoprotein K;
DE Short=hnRNP K;
DE AltName: Full=dC stretch-binding protein;
DE Short=CSBP;
GN Name=Hnrnpk; Synonyms=Hnrpk;
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC Murinae; Rattus.
OX NCBI_TaxID=10116;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC STRAIN=Donryu; TISSUE=Liver;
RX PubMed=8127654; DOI=10.1093/nar/22.1.53;
RA Ito K., Sato K., Endo H.;
RT "Cloning and characterization of a single-stranded DNA binding protein that
RT specifically recognizes deoxycytidine stretch.";
RL Nucleic Acids Res. 22:53-58(1994).
RN [2]
RP PROTEIN SEQUENCE OF 149-163, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC STRAIN=Sprague-Dawley; TISSUE=Hippocampus;
RA Lubec G., Chen W.-Q.;
RL Submitted (APR-2007) to UniProtKB.
RN [3]
RP INTERACTION WITH RBM42.
RX PubMed=19170760; DOI=10.1111/j.1365-2443.2008.01256.x;
RA Fukuda T., Naiki T., Saito M., Irie K.;
RT "hnRNP K interacts with RNA binding motif protein 42 and functions in the
RT maintenance of cellular ATP level during stress conditions.";
RL Genes Cells 14:113-128(2009).
RN [4]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-116, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX PubMed=22673903; DOI=10.1038/ncomms1871;
RA Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA Olsen J.V.;
RT "Quantitative maps of protein phosphorylation sites across 14 different rat
RT organs and tissues.";
RL Nat. Commun. 3:876-876(2012).
CC -!- FUNCTION: One of the major pre-mRNA-binding proteins. Binds tenaciously
CC to poly(C) sequences. Likely to play a role in the nuclear metabolism
CC of hnRNAs, particularly for pre-mRNAs that contain cytidine-rich
CC sequences. Can also bind poly(C) single-stranded DNA. Plays an
CC important role in p53/TP53 response to DNA damage, acting at the level
CC of both transcription activation and repression. When sumoylated, acts
CC as a transcriptional coactivator of p53/TP53, playing a role in
CC p21/CDKN1A and 14-3-3 sigma/SFN induction. As far as transcription
CC repression is concerned, acts by interacting with long intergenic RNA
CC p21 (lincRNA-p21), a non-coding RNA induced by p53/TP53. This
CC interaction is necessary for the induction of apoptosis, but not cell
CC cycle arrest (By similarity). As part of a ribonucleoprotein complex
CC composed at least of ZNF827, HNRNPL and the circular RNA circZNF827
CC that nucleates the complex on chromatin, may negatively regulate the
CC transcription of genes involved in neuronal differentiation (By
CC similarity). {ECO:0000250, ECO:0000250|UniProtKB:P61978}.
CC -!- SUBUNIT: Identified in the spliceosome C complex (By similarity).
CC Interacts with ANKRD28 and ZIK1 (By similarity). Interacts with DDX1
CC (By similarity). Interacts with MDM2; this interaction leads to
CC ubiquitination and proteasomal degradation (By similarity). Interacts
CC with p53/TP53 (By similarity). Interacts with BRDT (By similarity).
CC Interacts with RBM42 (PubMed:19170760). Interacts with IVNS1ABP (By
CC similarity). Interacts with PPIA/CYPA (By similarity). Part of a
CC transcription inhibitory ribonucleoprotein complex composed at least of
CC the circular RNA circZNF827, ZNF827 and HNRNPL (By similarity).
CC {ECO:0000250|UniProtKB:P61978, ECO:0000250|UniProtKB:P61979,
CC ECO:0000269|PubMed:19170760}.
CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P61978}.
CC Nucleus, nucleoplasm {ECO:0000250|UniProtKB:P61978}. Cell projection,
CC podosome {ECO:0000250|UniProtKB:P61978}.
CC -!- PTM: Sumoylated by CBX4. Sumoylation is increased upon DNA damage, such
CC as that produced by doxorubicin, etoposide, UV light and camptothecin,
CC due to enhanced CBX4 phosphorylation by HIPK2 under these conditions
CC (By similarity). {ECO:0000250}.
CC -!- PTM: Ubiquitinated by MDM2. Doxorubicin treatment does not affect
CC monoubiquitination, but slightly decreases HNRNPK poly-ubiquitination
CC (By similarity). {ECO:0000250}.
CC -!- PTM: O-glycosylated (O-GlcNAcylated), in a cell cycle-dependent manner.
CC {ECO:0000250}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; D17711; BAA04566.1; -; mRNA.
DR PIR; S41495; S41495.
DR RefSeq; NP_476482.1; NM_057141.1.
DR RefSeq; XP_006253616.1; XM_006253554.3.
DR AlphaFoldDB; P61980; -.
DR SMR; P61980; -.
DR BioGRID; 250729; 6.
DR IntAct; P61980; 84.
DR MINT; P61980; -.
DR STRING; 10116.ENSRNOP00000025980; -.
DR iPTMnet; P61980; -.
DR PhosphoSitePlus; P61980; -.
DR SwissPalm; P61980; -.
DR World-2DPAGE; 0004:P61980; -.
DR jPOST; P61980; -.
DR PaxDb; P61980; -.
DR PRIDE; P61980; -.
DR GeneID; 117282; -.
DR KEGG; rno:117282; -.
DR UCSC; RGD:71058; rat.
DR CTD; 3190; -.
DR RGD; 71058; Hnrnpk.
DR VEuPathDB; HostDB:ENSRNOG00000019113; -.
DR eggNOG; KOG2192; Eukaryota.
DR InParanoid; P61980; -.
DR Reactome; R-RNO-4570464; SUMOylation of RNA binding proteins.
DR Reactome; R-RNO-72163; mRNA Splicing - Major Pathway.
DR PRO; PR:P61980; -.
DR Proteomes; UP000002494; Chromosome 17.
DR Bgee; ENSRNOG00000019113; Expressed in thymus and 19 other tissues.
DR ExpressionAtlas; P61980; baseline and differential.
DR Genevisible; P61980; RN.
DR GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR GO; GO:0043679; C:axon terminus; IDA:RGD.
DR GO; GO:0071013; C:catalytic step 2 spliceosome; ISO:RGD.
DR GO; GO:0005938; C:cell cortex; IDA:RGD.
DR GO; GO:0000785; C:chromatin; ISS:UniProtKB.
DR GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR GO; GO:0010494; C:cytoplasmic stress granule; ISO:RGD.
DR GO; GO:0005829; C:cytosol; IDA:RGD.
DR GO; GO:0043197; C:dendritic spine; IDA:RGD.
DR GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR GO; GO:0005739; C:mitochondrion; IDA:RGD.
DR GO; GO:0005654; C:nucleoplasm; IEA:UniProtKB-SubCell.
DR GO; GO:0005634; C:nucleus; IDA:RGD.
DR GO; GO:0002102; C:podosome; IEA:UniProtKB-SubCell.
DR GO; GO:0098794; C:postsynapse; IDA:SynGO.
DR GO; GO:0014069; C:postsynaptic density; IDA:RGD.
DR GO; GO:0032993; C:protein-DNA complex; IDA:RGD.
DR GO; GO:1990904; C:ribonucleoprotein complex; ISS:UniProtKB.
DR GO; GO:0042805; F:actinin binding; IPI:RGD.
DR GO; GO:0051117; F:ATPase binding; IPI:RGD.
DR GO; GO:1990829; F:C-rich single-stranded DNA binding; IDA:RGD.
DR GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:RGD.
DR GO; GO:0003690; F:double-stranded DNA binding; IDA:RGD.
DR GO; GO:0031072; F:heat shock protein binding; IPI:RGD.
DR GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR GO; GO:0005521; F:lamin binding; IPI:RGD.
DR GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:RGD.
DR GO; GO:0003729; F:mRNA binding; IBA:GO_Central.
DR GO; GO:1990715; F:mRNA CDS binding; IDA:RGD.
DR GO; GO:0030628; F:pre-mRNA 3'-splice site binding; IDA:RGD.
DR GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR GO; GO:0043021; F:ribonucleoprotein complex binding; IDA:RGD.
DR GO; GO:0003723; F:RNA binding; ISO:RGD.
DR GO; GO:0003697; F:single-stranded DNA binding; IDA:RGD.
DR GO; GO:0006953; P:acute-phase response; IEP:RGD.
DR GO; GO:0007568; P:aging; IEP:RGD.
DR GO; GO:0043010; P:camera-type eye development; IEP:RGD.
DR GO; GO:0071230; P:cellular response to amino acid stimulus; IEP:RGD.
DR GO; GO:1904322; P:cellular response to forskolin; IDA:RGD.
DR GO; GO:0071333; P:cellular response to glucose stimulus; IEP:RGD.
DR GO; GO:0032869; P:cellular response to insulin stimulus; IDA:RGD.
DR GO; GO:0072752; P:cellular response to rapamycin; IEP:RGD.
DR GO; GO:0007417; P:central nervous system development; IEP:RGD.
DR GO; GO:0021549; P:cerebellum development; IEP:RGD.
DR GO; GO:0021987; P:cerebral cortex development; IDA:RGD.
DR GO; GO:0021766; P:hippocampus development; IEP:RGD.
DR GO; GO:0001822; P:kidney development; IEP:RGD.
DR GO; GO:0001889; P:liver development; IEP:RGD.
DR GO; GO:0030324; P:lung development; IEP:RGD.
DR GO; GO:0050804; P:modulation of chemical synaptic transmission; IMP:SynGO.
DR GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR GO; GO:2000173; P:negative regulation of branching morphogenesis of a nerve; IMP:RGD.
DR GO; GO:0010629; P:negative regulation of gene expression; IMP:RGD.
DR GO; GO:0048025; P:negative regulation of mRNA splicing, via spliceosome; ISO:RGD.
DR GO; GO:0032091; P:negative regulation of protein binding; IMP:RGD.
DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:RGD.
DR GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR GO; GO:0001541; P:ovarian follicle development; IMP:RGD.
DR GO; GO:0007422; P:peripheral nervous system development; IEP:RGD.
DR GO; GO:1903861; P:positive regulation of dendrite extension; IMP:RGD.
DR GO; GO:0060999; P:positive regulation of dendritic spine development; IMP:RGD.
DR GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; IMP:RGD.
DR GO; GO:1905599; P:positive regulation of low-density lipoprotein receptor activity; ISO:RGD.
DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:RGD.
DR GO; GO:2000010; P:positive regulation of protein localization to cell surface; IMP:RGD.
DR GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; ISO:RGD.
DR GO; GO:0033120; P:positive regulation of RNA splicing; IMP:RGD.
DR GO; GO:0090129; P:positive regulation of synapse maturation; IMP:RGD.
DR GO; GO:0050806; P:positive regulation of synaptic transmission; IMP:RGD.
DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR GO; GO:0010468; P:regulation of gene expression; IBA:GO_Central.
DR GO; GO:1902165; P:regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; ISO:RGD.
DR GO; GO:0010988; P:regulation of low-density lipoprotein particle clearance; ISO:RGD.
DR GO; GO:0048024; P:regulation of mRNA splicing, via spliceosome; IBA:GO_Central.
DR GO; GO:0099175; P:regulation of postsynapse organization; IDA:SynGO.
DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IMP:RGD.
DR GO; GO:0014823; P:response to activity; IEP:RGD.
DR GO; GO:1902074; P:response to salt; IEP:RGD.
DR GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR GO; GO:0048538; P:thymus development; IEP:RGD.
DR Gene3D; 3.30.1370.10; -; 3.
DR InterPro; IPR033090; hnRNP_K.
DR InterPro; IPR004087; KH_dom.
DR InterPro; IPR004088; KH_dom_type_1.
DR InterPro; IPR036612; KH_dom_type_1_sf.
DR InterPro; IPR012987; ROK_N.
DR PANTHER; PTHR10288:SF262; PTHR10288:SF262; 1.
DR Pfam; PF00013; KH_1; 3.
DR Pfam; PF08067; ROKNT; 1.
DR SMART; SM00322; KH; 3.
DR SUPFAM; SSF54791; SSF54791; 3.
DR PROSITE; PS50084; KH_TYPE_1; 3.
PE 1: Evidence at protein level;
KW Acetylation; Activator; Cell junction; Cell projection; Cytoplasm;
KW Direct protein sequencing; DNA-binding; Glycoprotein; Isopeptide bond;
KW Methylation; mRNA processing; mRNA splicing; Nucleus; Phosphoprotein;
KW Reference proteome; Repeat; Repressor; Ribonucleoprotein; RNA-binding;
KW Spliceosome; Transcription; Transcription regulation; Ubl conjugation.
FT CHAIN 1..463
FT /note="Heterogeneous nuclear ribonucleoprotein K"
FT /id="PRO_0000050099"
FT DOMAIN 42..104
FT /note="KH 1"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00117"
FT REPEAT 54..76
FT /note="1-1"
FT REPEAT 59..62
FT /note="3-1"
FT DOMAIN 144..209
FT /note="KH 2"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00117"
FT REPEAT 245..250
FT /note="2-1"
FT REPEAT 257..260
FT /note="3-2"
FT REPEAT 267..270
FT /note="3-3"
FT REPEAT 295..298
FT /note="3-4"
FT REPEAT 324..329
FT /note="2-2"
FT DOMAIN 387..451
FT /note="KH 3"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00117"
FT REPEAT 399..421
FT /note="1-2"
FT REPEAT 404..407
FT /note="3-5"
FT REGION 1..276
FT /note="Necessary for interaction with DDX1"
FT /evidence="ECO:0000250"
FT REGION 1..37
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 54..421
FT /note="2 X 22 AA approximate repeats"
FT REGION 59..407
FT /note="5 X 4 AA repeats of G-X-G-G"
FT REGION 209..337
FT /note="Interaction with ZIK1"
FT /evidence="ECO:0000250"
FT REGION 236..273
FT /note="RNA-binding RGG-box"
FT REGION 245..329
FT /note="2 X 6 AA approximate repeats"
FT REGION 250..329
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 19..37
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 1
FT /note="N-acetylmethionine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT MOD_RES 34
FT /note="N6-acetyllysine; alternate"
FT /evidence="ECO:0000250|UniProtKB:P61979"
FT MOD_RES 36
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT MOD_RES 39
FT /note="Phosphothreonine"
FT /evidence="ECO:0000250|UniProtKB:P61979"
FT MOD_RES 75
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT MOD_RES 116
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:22673903"
FT MOD_RES 198
FT /note="N6-acetyllysine"
FT /evidence="ECO:0000250|UniProtKB:P61979"
FT MOD_RES 214
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT MOD_RES 216
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT MOD_RES 219
FT /note="N6-succinyllysine; alternate"
FT /evidence="ECO:0000250|UniProtKB:P61979"
FT MOD_RES 284
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT MOD_RES 316
FT /note="Omega-N-methylarginine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT MOD_RES 377
FT /note="Omega-N-methylarginine"
FT /evidence="ECO:0000250|UniProtKB:P61979"
FT MOD_RES 379
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT MOD_RES 380
FT /note="Phosphotyrosine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT MOD_RES 405
FT /note="N6-acetyllysine; alternate"
FT /evidence="ECO:0000250|UniProtKB:P61979"
FT MOD_RES 420
FT /note="Phosphoserine"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 34
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO1); alternate"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 34
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2); alternate"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 52
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 60
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2)"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 163
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO1); alternate"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 163
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2); alternate"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 219
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2); alternate"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 405
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2); alternate"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 422
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO); alternate"
FT /evidence="ECO:0000250"
FT CROSSLNK 422
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO1); alternate"
FT /evidence="ECO:0000250|UniProtKB:P61978"
FT CROSSLNK 422
FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT G-Cter in SUMO2); alternate"
FT /evidence="ECO:0000250|UniProtKB:P61978"
SQ SEQUENCE 463 AA; 50976 MW; 0F70EE169B2A064A CRC64;
METEQPEETF PNTETNGEFG KRPAEDMEEE QAFKRSRNTD EMVELRILLQ SKNAGAVIGK
GGKNIKALRT DYNASVSVPD SSGPERILSI SADIETIGEI LKKIIPTLEE GLQLPSPTAT
SQLPLESDAV ECLNYQHYKG SDFDCELRLL IHQSLAGGII GVKGAKIKEL RENTQTTIKL
FQECCPHSTD RVVLIGGKPD RVVECIKIIL DLISESPIKG RAQPYDPNFY DETYDYGGFT
MMFDDRRGRP VGFPMRGRGG FDRMPPGRGG RPMPPSRRDY DDMSPRRGPP PPPPGRGGRG
GSRARNLPLP PPPPPRGGDL MAYDRRGRPG DRYDGMVGFS ADETWDSAID TWSPSEWQMA
YEPQGGSGYD YSYAGGRGSY GDLGGPIITT QVTIPKDLAG SIIGKGGQRI KQIRHESGAS
IKIDEPLEGS EDRIITITGT QDQIQNAQYL LQNSVKQYSG KFF
